Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3′,5′-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure;Wplyw digoksyny na stȩżenie przedsionkowego peptydu natriuretycznego, mózgowego peptydu natriuretycznego i cyklicznego 3′, 5′-guanozynomonofosforanu u chorych na przewlekla̧, zastoinowa̧ niewydolność serca

Polskie Archiwum Medycyny Wewnetrznej

Volumn 105, Issue 6, 2001, Pages 475-482

  Kobusiak Prokopowicz, Małgorzata ^a   Świdnicka Szuszkowska, Bernadeta ^a   Mysiak, Andrzej ^a  

^a Kat i Klinika Kardiologii AM we W   (Poland)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Congestive heart failure; Cyclic 3 ,5 guanosine monophosphate; Digoxin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIGOXIN; CARDIOTONIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEMODYNAMICS; HORMONE BLOOD LEVEL; HUMAN; MALE; NEUROENDOCRINE SYSTEM; SECOND MESSENGER; TREATMENT OUTCOME; BLOOD; CASE CONTROL STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; CYCLIC GMP; DIGOXIN; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035382661     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Yoshikawa T., Baba A., Akashi M. i wsp.: Neurohumoral activations in congestive heart failure: Correlations with cardiac function, heart rate variability, and baroreceptor sensivity. Am. Heart J., 1998, 137, 666.
2. Bonatti J., Dichtl W., Diworzak E.A. i wsp.: Atrial natriuretic peptide-induced release of cyclic guanosine monophosphate by coronary bypass grafts. Ann Thorac. Surg., 1998, 65, 1621.
3. Ferguson D.W.: Digitalis and neurohumoral abnormalities in heart failure and implications for therapy. Am. J. Cardiol., 1992, 69, 24G.
4. Tsutamoto T., Wada A., Maeda K. i wsp.: Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am. Heart. J., 1997, 134, 910-916.
5. Murdoch D.R., Byrne J., Morton J.J. i wsp.: Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implication for clinical practice. Heart 1997, 78, 594.
6. Nakamura M., Arakawa N., Yoshida H. i wsp.: Vasodilatatory efects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J., 1998, 135, 414.
7. Globits S., Frank H., Pacher B. i wsp.: Atrial natriuretic peptide release is more dependent on atrial filling volume than on of filling pressure in chronic congestive heart failure. Am. Heart J., 1998, 135, 592.
8. McDonagh T.A., Robb S.D., Murdoch D.R. i wsp.: Biochemical detection of left-ventricular systolic dysfunction. Lancet, 1998, 351, 9.
9. Omland T., Aakvaag A., Vik-Mo H.: Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart, 1996, 76, 232.
10. Maeda K., Tsutamoto T., Wada A. i wsp.: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J., 1998, 135, 825.
11. Muders F., Kromer P., Griese D.P. i wsp.: Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am. Heart J. 1997, 134, 442.
12. Van der Berg M., Crijns H.J.G.M., Van Veldhuisen D.J. i wsp.: Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation. Role of duration of atrial fibrillation. Am. Heart J., 1998, 135, 242.
13. The DIG Investigation group.: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med., 1997, 336, 525.
14. th Annual Scientific Session, New Orleans, USA, 1999.
15. Massie M.B., Abdalla I.: Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog. in Cardiovascular Diseases, 1998, 40, 357.
16. Riaz K., Forker A.D.: Digoxin use in congestive heart failure. Drugs 1998, 55, 747-758.
17. Reddy S., Benator D., Gheorghiade M. : Update on digoxin and other oral positive inotropic agents for chronic heart failure. Curr. Opin. Cardiol., 1997, 12, 233.